Spyre Therapeutics (FRA:3920) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3920 Spyre Therapeutics Inc FRA:3920
29 GF Score
Price €75.50
GF Value €1.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Spyre Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:3920
29GF Score
Spyre Therapeutics Inc FRA:3920
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?

Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued. The current stock price of €75.50 is trading 3713.1% above its estimated GF Value™ of €1.98. GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:3920:

  • Short Ratio:
  • GF Value™: €1.98 vs. price of €75.50 (3713.1% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score

Get the complete analysis for FRA:3920

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.50
Price
€1.98
GF Value